Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.

Weisberg EL, Sattler M, Azab AK, Eulberg D, Kruschinski A, Manley PW, Stone R, Griffin JD.

Oncotarget. 2017 Nov 6;8(66):109973-109984. doi: 10.18632/oncotarget.22409. eCollection 2017 Dec 15.

2.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.

J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.

PMID:
29196043
3.

Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK.

J Pharm Sci. 2018 Mar;107(3):922-933. doi: 10.1016/j.xphs.2017.10.042. Epub 2017 Nov 21.

4.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
5.

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.

Muz B, Azab F, de la Puente P, Landesman Y, Azab AK.

Transl Oncol. 2017 Aug;10(4):632-640. doi: 10.1016/j.tranon.2017.04.010. Epub 2017 Jun 29.

6.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK.

Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.

7.

Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.

de la Puente P, Azab AK.

Eur J Haematol. 2017 Jun;98(6):529-541. doi: 10.1111/ejh.12870. Epub 2017 Mar 28. Review.

8.

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.

Burwick N, Zhang MY, de la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M, Sanchez-Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A.

Leuk Res. 2017 Apr;55:23-32. doi: 10.1016/j.leukres.2017.01.007. Epub 2017 Jan 12.

9.

Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Imai T, Muz B, Yeh CH, Yao J, Zhang R, Azab AK, Wang L.

Cancer Biol Ther. 2017 Feb;18(2):101-105. doi: 10.1080/15384047.2016.1276137. Epub 2017 Jan 3.

10.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.

Muz B, de la Puente P, Azab F, Azab AK.

Hypoxia (Auckl). 2015 Dec 11;3:83-92. eCollection 2015. Review.

11.

Drug Delivery Approaches for the Treatment of Cervical Cancer.

Ordikhani F, Erdem Arslan M, Marcelo R, Sahin I, Grigsby P, Schwarz JK, Azab AK.

Pharmaceutics. 2016 Jul 20;8(3). pii: E23. doi: 10.3390/pharmaceutics8030023. Review.

12.

A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma.

Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK.

Pharm Res. 2016 Oct;33(10):2530-9. doi: 10.1007/s11095-016-1977-2. Epub 2016 Jul 11.

13.

3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

de la Puente P, Azab AK.

Future Oncol. 2016 Jul;12(13):1545-7. doi: 10.2217/fon-2016-0057. Epub 2016 Mar 30. No abstract available.

PMID:
27333447
14.

Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.

de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK.

Haematologica. 2016 Jul;101(7):e307-11. doi: 10.3324/haematol.2016.142190. Epub 2016 Apr 14. No abstract available.

15.

Biological Insights into Myeloma and Other B Cell Malignancies.

Fulciniti M, Amodio N, Cea M, Maiso P, Azab AK.

Biomed Res Int. 2016;2016:5218093. doi: 10.1155/2016/5218093. Epub 2016 Feb 16. No abstract available.

16.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.

de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK.

Blood Cancer J. 2016 Feb 26;6:e399. doi: 10.1038/bcj.2016.7. No abstract available.

17.

Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK.

Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016. Review.

18.

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK.

Br J Haematol. 2016 Apr;173(1):70-81. doi: 10.1111/bjh.13927. Epub 2016 Jan 5.

19.

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.

Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK.

Biomed Res Int. 2015;2015:417586. doi: 10.1155/2015/417586. Epub 2015 Oct 11.

20.

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK.

Leuk Lymphoma. 2016 Jul;57(7):1677-86. doi: 10.3109/10428194.2015.1099645. Epub 2015 Nov 16.

21.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

22.

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK.

Biomaterials. 2015 Dec;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. Epub 2015 Sep 12.

23.

Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice.

Kapoor V, Khudanyan A, de la Puente P, Campian J, Hallahan DE, Azab AK, Thotala D.

Cancer Res. 2015 Sep 1;75(17):3442-5. doi: 10.1158/0008-5472.CAN-15-1412. Epub 2015 Jun 30.

24.

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.

Luderer MJ, de la Puente P, Azab AK.

Pharm Res. 2015 Sep;32(9):2824-36. doi: 10.1007/s11095-015-1718-y. Epub 2015 Jun 2. Review.

PMID:
26033767
25.

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Blood Cancer J. 2014 Dec 5;4:e262. doi: 10.1038/bcj.2014.82. No abstract available.

26.

Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.

Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK.

Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150. Epub 2014 Sep 17.

27.

The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Mol Cancer Res. 2014 Oct;12(10):1347-54. doi: 10.1158/1541-7786.MCR-14-0028. Epub 2014 Aug 26. Review.

28.

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

Azab AK, Sahin I, Moschetta M, Mishima Y, Burwick N, Zimmermann J, Romagnoli B, Patel K, Chevalier E, Roccaro AM, Ghobria IM.

Blood. 2014 Sep 18;124(12):1905-14.

29.

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.

Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, Roccaro AM, Azab AK, Ghobrial IM.

Am J Hematol. 2014 Nov;89(11):1030-6. doi: 10.1002/ajh.23814. Epub 2014 Aug 12.

30.

Delivery systems for brachytherapy.

de la Puente P, Azab AK.

J Control Release. 2014 Oct 28;192:19-28. doi: 10.1016/j.jconrel.2014.06.057. Epub 2014 Jul 5. Review.

PMID:
25008970
31.

The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.

Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM.

Lab Invest. 2014 Aug;94(8):881-92. doi: 10.1038/labinvest.2014.78. Epub 2014 Jun 23.

32.

Molecularly targeted therapies in multiple myeloma.

de la Puente P, Muz B, Azab F, Luderer M, Azab AK.

Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16. Review.

33.

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.

Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, Roccaro AM, Ghobrial IM.

Blood Cancer J. 2014 Apr 25;4:e204. doi: 10.1038/bcj.2014.24. No abstract available.

34.

The role of P-glycoprotein in drug resistance in multiple myeloma.

Abraham J, Salama NN, Azab AK.

Leuk Lymphoma. 2015 Jan;56(1):26-33. doi: 10.3109/10428194.2014.907890. Epub 2014 Jun 5. Review.

PMID:
24678978
35.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.

Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK.

Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734. Epub 2014 Jan 9.

PMID:
24405121
36.

Contemporary drug therapies for multiple myeloma.

de la Puente P, Azab AK.

Drugs Today (Barc). 2013 Sep;49(9):563-73. doi: 10.1358/dot.2013.49.9.2020941. Review.

PMID:
24086952
37.

Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.

Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM.

PLoS One. 2013 Jun 13;8(6):e66982. doi: 10.1371/journal.pone.0066982. Print 2013.

38.

Cell trafficking of endothelial progenitor cells in tumor progression.

de la Puente P, Muz B, Azab F, Azab AK.

Clin Cancer Res. 2013 Jul 1;19(13):3360-8. doi: 10.1158/1078-0432.CCR-13-0462. Epub 2013 May 10. Review.

39.

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM.

J Clin Invest. 2013 Apr;123(4):1542-55. Erratum in: J Clin Invest. 2013 Aug 1;123(8):3635.

40.

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression.

Azab AK, Weisberg E, Sahin I, Liu F, Awwad R, Azab F, Liu Q, Griffin JD, Ghobrial IM.

Leukemia. 2013 Apr;27(4):961-4. doi: 10.1038/leu.2012.353. Epub 2012 Dec 5. No abstract available.

PMID:
23212153
41.

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.

Roccaro AM, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM.

Clin Cancer Res. 2012 Dec 15;18(24):6609-22. doi: 10.1158/1078-0432.CCR-12-1532. Epub 2012 Oct 9.

42.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC.

Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20.

43.

LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.

Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM.

Blood. 2012 Aug 23;120(8):1678-86. doi: 10.1182/blood-2012-02-410647. Epub 2012 Jul 13.

44.

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM.

Blood. 2012 Jun 14;119(24):5782-94. doi: 10.1182/blood-2011-09-380410. Epub 2012 Mar 6.

45.

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD.

Leukemia. 2012 May;26(5):985-90. doi: 10.1038/leu.2011.360. Epub 2011 Dec 20.

46.

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.

Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monrose V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, Roccaro AM, Ghobrial IM.

Blood. 2012 Feb 9;119(6):1468-78. doi: 10.1182/blood-2011-07-368050. Epub 2011 Nov 16.

47.

Defining the role of TORC1/2 in multiple myeloma.

Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM.

Blood. 2011 Dec 22;118(26):6860-70. doi: 10.1182/blood-2011-03-342394. Epub 2011 Nov 1.

48.

Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia.

Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, Roccaro AM, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM.

Clin Cancer Res. 2012 Jan 1;18(1):91-104. doi: 10.1158/1078-0432.CCR-11-0111. Epub 2011 Oct 18.

49.

FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.

Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM.

Clin Cancer Res. 2011 Jul 1;17(13):4389-99. doi: 10.1158/1078-0432.CCR-10-2772. Epub 2011 Apr 26.

50.

Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.

Neri P, Ren L, Azab AK, Brentnall M, Gratton K, Klimowicz AC, Lin C, Duggan P, Tassone P, Mansoor A, Stewart DA, Boise LH, Ghobrial IM, Bahlis NJ.

Blood. 2011 Jun 9;117(23):6202-13. doi: 10.1182/blood-2010-06-292243. Epub 2011 Apr 7.

Supplemental Content

Support Center